Abstract: Three series of 4,6-dimethoxy-, 4,6-dipiperidino-and 4,6-dimorpholino-1,3,5-triazin-2-yl) amino acid derivatives were synthesized and characterized. A preliminary study for their monoamine oxidase inhibitory activity showed that compounds 7, 18, and 25 had MAO-A inhibition activity comparable to that of the standard clorgyline, with apparently more selective inhibitory activity toward MAO-A than MAO-B and no significant acute toxicity.
Introduction
Human monoamine oxidases A and B (MAO-A and B) are the most widely studied flavin-dependent amine oxidases. They are located in the mitochondrial outer membranes of neuronal, glial, and other cells particularly abundant in the liver and brain [1, 2] . These FAD-dependent enzymes catalyze the oxidative deamination of several endogenous and exogenous monoamines and are responsible for the regulation and metabolism of major monoamine neurotransmitters, such as serotonin (5-OH tryptamine), noradrenaline, and dopamine [1] [2] [3] . The two mammalian isoforms of these enzymes are characterized by their distinct sensitivity to inhibitors and specificity to substrates. Thus, MAO-A is selectively inhibited by clorgyline and preferentially metabolizes serotonin: whereas MAO-B is inhibited by L-deprenyl and preferentially metabolizes benzylamine and phenylethylamine as substrates [4] . Among selective MAO inhibitors, those against MAO-A are used as anti-depressant and anti-anxiety drugs and have been claimed to protect neuronal cells against apoptosis [5, 6] . In contrast, MAO-B inhibitors have been found to be beneficial in the treatment of Parkinson's disease and Alzheimer's disease. Early MAO-inhibitors introduced into clinical practice for the treatment of depression were abandoned due to adverse side effects, such as the "cheese effect", which is characterized by hypertensive crises [4] , and because the mechanism of interaction of several new drugs with MAOs has not been yet fully characterized. For these reasons, research has been aimed at the synthesis of new potential agents with clinical applications.
Recently, we have demonstrated a series of 3-benzyl-2-substituted quinoxalines as selective MAO-A inhibitors bearing substituted amino or hydrazino functionalities at position 2 [7] and novel structural variants of [1, 2, 4] triazolo [4,3-a] quinoxaline derivatives [8] . In addition, substituted pyridazine-1-yl acetic acid derivatives [9] , and α-ketoamino acid ester derivatives [10] were established as selective monoamine oxidase-A inhibitors.
1,3,5-triazine derivatives are an important class of small molecules with anti-cancer [11] [12] [13] [14] [15] [16] and anti-viral activity, among others [17] . These compounds are known to be VLA-4 integrin antagonists, anti-inflammatory agents [18] , sorbitol dehydrogenase inhibitors [19] , estrogen receptor modulators [20] , potential anti-trypanosomal drugs [21] , antimalarial agents [22] [23] [24] [25] [26] [27] [28] [29] , hypolipidemic agents, [30] and antimicrobial agents [31] [32] [33] .
Here, we prepared three small libraries of molecules based on amino acid-substituted 1,3,5-triazine and evaluated their capacity to inhibit MOAs.
The aim of the present study was to tailor MAO-A inhibitors by designing a hybrid from different possible active sites of previously known MAO-A inhibitors, based on the following considerations: (i) the presence of electron-rich aromatic moieties (e.g., moclobemide [34] ,bazinaprine [35] , quinoxaline derivatives [7, 8] ); (ii) the presence of morpholine moiety (e.g., moclobemide [34] , bazinaprine [35] ); and (iii) the presence of amino acid moiety [9, 10] ). The target compounds were designed to study the effect of molecular variation on MAO inhibitory activity, Figure 1. 
Results and Discussion

Chemistry
We replaced two chlorine atoms with cyanuric chloride and two methoxy, two piperidino or two morpholino groups, while the third chlorine was replaced with free α-amino acid. Accordingly, 4,6-dimethoxy-, 4,6-dipiperidino-and 4,6-dimorpholino-1,3,5-triazine-based amino acid derivatives were prepared by subsequent displacement of chlorine atoms.
Figure 1.
Planned modification and newly designed MAO inhibitors. I = (4,6-dimethoxy-1,3,5-triazin-2-yl) amino acid derivatives; X = O; II is (4,6-dimorpholino-1,3,5-triazin-2-yl) amino acid derivatives or X = CH2; II is (4,6-dipiperidino-1,3,5-triazin-2-yl) amino acid derivatives.
The small library of (4,6-dimethoxy-1,3,5-triazin-2-yl) amino acid derivatives 3-9 were prepared by reaction of 2-chloro-4,6-dimethoxy triazine 1 and α-amino acids in the presence of triethyl amine as acid scavenger in a 1,4-dioxane/water (1:1) solvent mixture at room temperature (Scheme 1). The reaction was started by addition of N,N,N-triethyl amine (Et3N) to a solution of 2-chloro-4,6-dimethoxy triazine 1 in 1,4-dioxane and stirring until a white suspension of 4,6-dimethoxy-1,3,5-triazin-2-yl triethyl ammonium chloride salt 2 was formed. An aqueous solution of α-amino acid and Et3N was then added to this white suspension and stirred to give the desired products after neutralization with 5% citric acid or 1 N HCl. The structures of compounds 3-9 were confirmed by spectroscopic methods (IR, Two singlet peaks at δ 3.77 ppm and 3.80 ppm corresponding to the two methoxy groups were observed. A multiplet peak appeared at δ 4.54-4.59 ppm corresponding to the α-proton. The peaks corresponding to the aromatic protons appeared as a multiplet at δ 7.18-7.31 ppm. A doublet peak at δ 8.20 ppm with J = 8.0 Hz, which is D2O-exchangeable, was also observed, corresponding to the NH proton (Supplementary Data Figure S9 ). Scheme 1. Synthesis of (4,6-dimethoxy-1,3,5-triazin-2-yl) amino acid derivatives 3-9. In addition, N-(4,6-dipiperidino/dimorpholino-1,3,5-triazin-2-yl) amino acid derivatives 15-28 were prepared through the following sequential reaction: cyanuric chloride 10 was reacted first with piperidine/morpholine in the presence of sodium carbonate (acid scavenger) to afford the corresponding products 2,4-dichloro-6-(piperidin-1-yl)-1,3,5-triazine 11 and 2,4-dichloro-6-morpholino-1,3,5-triazine 12 [28] , respectively. Compounds 11 or 12 were allowed to react with free α-amino acids at room temperature. The formed products 13 and 14, respectively, were then allowed to react directly without isolation with piperidine/morpholine in the presence of Et3N, to give the corresponding products, N- (4,6-dipiperidino-1,3,5-triazin-2-yl) amino acid derivatives 15-21 and N- (4,6-dimorpholino-1,3,5- triazin-2-yl) amino acid derivatives 22-28 (Scheme 2).
Compounds 29 or 30 were prepared by reaction of cyanuric chloride with equiv. of piperidine/morpholine in the presence of Et3N (Scheme 2) [36] . In contrast, the preparation of N-(4,6-dipiperidino/dimorpholino-1,3,5-triazin-2-yl) amino acid derivatives through the reaction of free α-amino acids with 29/30 was not successful (Scheme 2). The difficulty to displace the third chlorine by the rather weak nucleophilicity of the amino group of α-amino acids can be attributed to the presence of two electron-donating piperidine/ morpholine groups, which decreases the positivity of the third chlorine-bearing carbon and prevents the 
Scheme 2. Synthesis of N-(4,6-dipiperidino/dimorpholino-1,3,5-triazin-2-yl) amino acid derivatives 15-28.
Preliminary Biology
The newly synthesized compounds 3-9 and 15-28 were tested to determine selectivity for MAO-A and MAO-B in the presence of the specific substrate serotonin or benzylamine, respectively. Compounds 7, 18, and 25 showed MAO-A inhibition activity comparable to that of the standard clorgyline with apparently more selective inhibitory activity toward MAO-A than MAO-B, and without no significant acute toxicity. More formal studies to confirm these preliminary results will be carried out and published elsewhere.
Experimental Section
Chemistry
Solvents and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Unless otherwise stated, the normal workup from organic solvent involved drying over Na2SO4 and rotary evaporation. A solution of 2-chloro-4,6-dimethoxy triazine 1 (0.88 g, 5 mmol) and triethyl amine (1.04 mL, 7.5 mmol) in dioxane was stirred at room temperature until a white suspension of 4,6-dimethoxy-1,3,5-trazin-2-yl triethyl ammonium chloride was formed. A solution of α-amino acid (5 mmol) and triethyl amine (1.04 mL, 7.5 mmol) in 6 mL dioxane:water (1:1) was added to the white suspension, forming a clear mixture. The mixture was stirred overnight and then neutralized with 1N HCl to yield a white solid, which was then filtered and dried. (8 
N-(4,6-Dimethoxy-1,3,5-triazin-2-yl)iminodiacetic acid (3)
.
2-(4,6-Dimethoxy-1,3,5-triazin-2-ylamino)-4-methylpentanoic acid
2-(4,6-Dimethoxy-1,3,5-triazin-2-ylamino)-3-methylpentanoic acid (9)
General Procedure for the Synthesis of N-(4,6-Dipiperidino-1,3,5-triazin-2-yl) Amino Acid Derivatives 15-21
A mixture of 2,4-dichloro-6-(piperidin-1-yl)-1,3,5-triazine 11 (0.47 g, 2 mmol) and triethyl amine (0.42 mL, 3 mmol) in 1,4-dioxane (5 mL) was stirred at room temperature until a white suspension was formed. A solution of α-amino acid (2.4 mmol) and triethyl amine (0.42 mL, 3 mmol) in water (2 mL) was added to the suspension to afford a clear mixture. The mixture was stirred overnight at room temperature. Subsequently, piperidine (0.3 mL, 3 mmol) and triethyl amine (0.56 mL, 4 mmol) were added to the reaction mixture and stirred at between 75 °C and 80 °C for 5 h. The reaction mixture was neutralized with 5% citric acid or 1 N HCl. The white precipitate was filtered and recrystallized from ethanol/water to obtain the desired products. (15 (16 (19) . The product was obtained as a white solid, 0.67 g (82.0%) yield; mp: 132-134 °C; IR (KBr): 3571-2853 (br, OH, acid), 3316 (NH, amine), 1721 (CO, acid) cm (20) . The product was obtained as a white solid, 0.54 g (71.8%) yield; mp:158-161 °C; IR (KBr): 3614-2855 (br, OH, acid), 3320 (NH, amine) 1721 (CO, acid) cm The mixture of 2,4-dichloro-6-morpholino-1,3,5-triazine 12 (0.47 g, 2 mmol) and triethyl amine (0.42 mL, 3 mmol) in 1,4-dioxane (5 mL) was stirred at room temperature until a white suspension was formed. A solution of α-amino acid (1.2 equiv.) and triethyl amine (0.42 mL, 3 mmol) in water (2 mL) was added to the suspension to afford a clear mixture. The mixture was stirred overnight at room temperature. Subsequently, morpholine (0.26 mL, 3 mmol) and triethyl amine (0.56 mL, 4 mmol) were added to the reaction mixture and stirred at between 75 °C and 80 °C for 5 h. The reaction mixture was neutralized with 5% citric acid or 1 N HCl. The white precipitate was filtered and recrystallized from ethanol/water to obtain the desired products. , N-H (27) . The product was obtained as a white solid, 0.48 g (62.7%) yield; mp: 120-122 °C; IR (KBr): 3720-2500 (br, OH, acid), 3426 (NH, amine), 1728 (CO, acid) cm 
N-(4,6-Dipiperidino-1,3,5-triazin-2-yl)iminodiacetic acid
2-(4,6-Di(piperidin-1-yl)-1,3,5-triazin-2-ylamino)acetic acid
2-(4,6-Di(piperidin-1-yl)-1,3,5-triazin-2-ylamino)-3-methylbutanoic acid (18)
2-(4,6-Di(piperidin-1-yl)-1,3,5-triazin-2-ylamino)-3-phenylpropanoic acid
2-(4,6-Di(piperidin-1-yl)-1,3,5-triazin-2-ylamino)-4-methylpentanoic acid
2-(4,6-Dimorpholino-1,3,5-triazin-2-ylamino)-4-methylpentanoic acid
Conclusions
The synthesis and a preliminary biochemical evaluation of the newly synthesized  N-(2,4-disubstituted-1,3 ,5-triazin-2-yl) amino acid derivatives as MAO inhibitors were described. Compounds 7, 18 and 25 showed the highest activity within the test compounds comparable to that of the standard clorgyline. These preliminary tests have also shown remarkable selectivity within the test compounds as MAO-A inhibitors. Therefore, such compounds would represent a fruitful matrix for the development of a new class of MAO-A inhibitors that would deserve further investigation and derivatization.
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